Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene T
Go back to Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene T| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 19.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.76 | 52 Week High | $63.73 | |||
| Open | $19.76 | 52 Week Low | $8.00 | |||
| Day High | $19.76 | P/E | N/A | |||
| Day Low | $19.76 | EPS | $-5.69 | |||
| Volume | 283 | |||||
